Horizon Therapeutics (HZNP) Tops Q4 EPS by 22c, Revenues Beat; Offers FY21 Revenue Guidance Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/14/2026

1. CSCO
2. CBRS
3. COHR
4. SPY
5. BTGO
6. NVDA
7. WYFI
8. STUB
9. EAT
10. BIRK

Go back to Horizon Therapeutics (HZNP) Tops Q4 EPS by 22c, Revenues Beat; Offers FY21 Revenue Guidance Above Consensus

Horizon Therapeutics (HZNP) PT Raised to $115 at BMO Capital

February 22, 2021 12:08 AM EST

BMO Capital analyst Gary Nachman raised the price target on Horizon Therapeutics (NASDAQ: HZNP) to $115.00 (from $110.00) while maintaining a Outperform rating.

The analyst comments "We updated our HZNP model incorporating VIE acquisition announced 2/1, and recent comments on opex and Tepezza/Krystexxa trends (exceeded 2020 guidance),... More